These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31580700)

  • 1. Characterization of HIV-1 CRF01_AE
    Sasaki M; Kotaki T; Khairunisa SQ; Tachibana S; Ophinni Y; Hayashi Y; Nasronudin ; Kameoka M
    AIDS Res Hum Retroviruses; 2020 Mar; 36(3):242-247. PubMed ID: 31580700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected Thai individuals.
    Chaitaveep N; Utachee P; Nakamura S; Chuenchitra T; Ekpo P; Takeda N; Pattanapanyasat K; Kameoka M
    Microbes Infect; 2014 Feb; 16(2):142-52. PubMed ID: 24513704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and Phenotypic Analysis of CRF01_AE HIV-1 env Clones from Patients Residing in Beijing, China.
    Chen D; He X; Ye J; Zhao P; Zeng Y; Feng X
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1113-1124. PubMed ID: 27066910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic and phenotypic characterization of HIV-1 CRF01_AE env molecular clones from infections in China.
    Nie J; Zhang C; Liu W; Wu X; Li F; Wang S; Liang F; Song A; Wang Y
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):440-50. PubMed ID: 20090544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.
    Sapsutthipas S; Tsuchiya N; Pathipavanich P; Ariyoshi K; Sawanpanyalert P; Takeda N; Isarangkura-na-ayuthaya P; Kameoka M
    PLoS One; 2013; 8(1):e53920. PubMed ID: 23308290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P; Korber BT; Lapedes AS; Bailer RT; Seaman MS; Gao H; Greene KM; McCutchan F; Williamson C; Kim JH; Tovanabutra S; Hahn BH; Swanstrom R; Thomson MM; Gao F; Harris L; Giorgi E; Hengartner N; Bhattacharya T; Mascola JR; Montefiori DC
    J Virol; 2014 Nov; 88(21):12623-43. PubMed ID: 25142591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backbone.
    Chenine AL; Wieczorek L; Sanders-Buell E; Wesberry M; Towle T; Pillis DM; Molnar S; McLinden R; Edmonds T; Hirsch I; O'Connell R; McCutchan FE; Montefiori DC; Ochsenbauer C; Kappes JC; Kim JH; Polonis VR; Tovanabutra S
    PLoS One; 2013; 8(11):e76104. PubMed ID: 24312165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.
    Utachee P; Jinnopat P; Isarangkura-Na-Ayuthaya P; de Silva UC; Nakamura S; Siripanyaphinyo U; Wichukchinda N; Tokunaga K; Yasunaga T; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    Microbes Infect; 2009 Mar; 11(3):334-43. PubMed ID: 19136072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand.
    Utachee P; Jinnopat P; Isarangkura-Na-Ayuthaya P; de Silva UC; Nakamura S; Siripanyaphinyo U; Wichukchinda N; Tokunaga K; Yasunaga T; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):229-36. PubMed ID: 19108694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
    Kuriakose Gift S; Wieczorek L; Sanders-Buell E; Zemil M; Molnar S; Donofrio G; Townsley S; Chenine AL; Bose M; Trinh HV; Barrows BM; Sriplienchan S; Kitsiripornchai S; Nitayapan S; Eller LA; Rao M; Ferrari G; Michael NL; Ake JA; Krebs SJ; Robb ML; Tovanabutra S; Polonis VR
    J Virol; 2023 Feb; 97(2):e0163522. PubMed ID: 36749076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
    Wang S; Nie J; Wang Y
    Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
    PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.
    Kumar A; Smith CEP; Giorgi EE; Eudailey J; Martinez DR; Yusim K; Douglas AO; Stamper L; McGuire E; LaBranche CC; Montefiori DC; Fouda GG; Gao F; Permar SR
    PLoS Pathog; 2018 Apr; 14(4):e1006944. PubMed ID: 29672607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.